160 related articles for article (PubMed ID: 16909812)
1. Development of nasal skin necrosis associated with rituximab treatment for Waldenström's macroglobulinemia and subsequent spontaneous resolution.
Pearlman AN; Fechner FP; Constantinides M
Ear Nose Throat J; 2006 Jul; 85(7):431-3. PubMed ID: 16909812
[TBL] [Abstract][Full Text] [Related]
2. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
3. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia.
Mauermann ML; Ryan ML; Moon JS; Klein CJ
J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458
[TBL] [Abstract][Full Text] [Related]
4. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab.
Buda-Okreglak EM; Drabick JJ; Delaney NR
Ann Hematol; 2004 Feb; 83(2):117-9. PubMed ID: 14513285
[TBL] [Abstract][Full Text] [Related]
5. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
6. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Waldenstrom's macroglobulinemia with "deck-chair" sign treated with cyclophosphamide.
Autier J; Buffet M; Pinquier L; Merlat-Guitard AI; Carlotti A; Franck N; Gorin I; Dupin N
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):45-7. PubMed ID: 15692513
[TBL] [Abstract][Full Text] [Related]
10. A review of rituximab in cutaneous medicine.
Scheinfeld N
Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
[TBL] [Abstract][Full Text] [Related]
11. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
Noronha V; Fynan TM; Duffy T
J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
[No Abstract] [Full Text] [Related]
12. Gangrenous, hemorrhagic, bullous cellulitis associated with pseudomonas aeruginosa in a patient with Waldenström's macroglobulinemia.
Falagas ME; Pappas VD; Michalopoulos A
Infection; 2007 Oct; 35(5):370-3. PubMed ID: 17721738
[TBL] [Abstract][Full Text] [Related]
13. [Association of sarcoidosis and Waldenström's macroglobulinemia].
Collet E; Boulitrop-Morvan C; Dalac S; Camus P; Lambert D
Ann Dermatol Venereol; 1992; 119(12):971-4. PubMed ID: 1304690
[TBL] [Abstract][Full Text] [Related]
14. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
15. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
18. [Waldenstrom's macroglobulinemia with antibasement membrane activity of monoclonal immunoglobulin].
Pech JH; Moreau-Cabarrot A; Oksman F; Bedane C; Bernard P; Bazex J
Ann Dermatol Venereol; 1997; 124(4):325-8. PubMed ID: 9739939
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
20. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
